What is InxMed?
Founded in 2018, InxMed operates as a specialized biotech entity with a dual focus on disease biology and clinical proof-of-concept. The company has established a robust operational presence across Shanghai, Beijing, Nanjing, the United States, Canada, and Australia, facilitating a truly global approach to drug development. Its core competency lies in its ability to navigate the complexities of the stroma microenvironment, a critical factor in tumor metastasis and therapeutic resistance.
InxMed distinguishes itself through a highly differentiated pipeline and strategic alliances with global pharmaceutical leaders, including Merck, Roche, and Boehringer Ingelheim. This collaborative model allows the firm to leverage external expertise while maintaining its internal focus on high-impact translational medicine, ensuring that its innovative therapies move efficiently from the laboratory to clinical application.
How much funding has InxMed raised?
InxMed has raised a total of $84M across 2 funding rounds:
Series A
$19M
Series B
$65M
Series A (2020): $19M with participation from InnoMed Capital, Grand Yangtze Capital, Ennovation Ventures, and China Growth Capital
Series B (2022): $65M led by Hosencare Fund, eNNOVATE Health Ventures, Growth Fund, AIHC Fund, and CS Capital
Key Investors in InxMed
CS Capital
CS Capital provides essential financial support and strategic guidance to emerging businesses, assisting founders in navigating complex capital markets and preparing for public listings.
Grand Yangtze Capital
A private equity firm focused on healthcare and intelligent manufacturing, Grand Yangtze Capital leverages deep industry expertise to support the growth of future market leaders in China.
China Growth Capital
China Growth Capital is a venture capital and private equity firm based in Beijing that specializes in identifying and scaling high-potential enterprises within the Chinese market.
What's next for InxMed?
With the recent infusion of capital, InxMed is poised to scale its clinical development operations and deepen its research into drug resistance mechanisms. The strategic roadmap involves accelerating the proof-of-concept platform to validate new therapeutic candidates, thereby enhancing the company's value proposition for future licensing or co-development opportunities. As the firm continues to build its translational medicine team, the focus will remain on bridging the gap between fundamental biological research and patient-centric clinical outcomes.
The company is well-positioned to leverage its existing partnerships to navigate the regulatory and commercial hurdles inherent in the global biotech sector. By maintaining a rigorous focus on scientific excellence and strategic resource allocation, InxMed aims to solidify its status as a leader in the next generation of oncology therapeutics, ultimately driving long-term value for stakeholders and improving outcomes for patients facing treatment-resistant solid tumors.
